Epigenetic reprogramming accompanies the transition to an osimertinib-tolerant state in EGFR-mutant HCC827 cells, and targeting HDACs and sirtuins may represent a promising strategy to eliminate DTP subpopulations and delay or prevent acquired resistance.
Public transcriptomic datasets from tumour cell-based models treated with EGFR inhibitors or other targeted agents within the receptor tyrosine kinase (RTK)/RAS/MAPK pathway were integrated with machine-learning-based feature selection, survival analysis and Cancer Dependency Map-based pharmacogenomic screening to defi...
Wen-Wen Chang, Jia-Xin Yuan, Hui-Lin Zhang et al.· Molecular Medicine Reports· 0 citations
The immune landscape of T-SCLC is more immunosuppressed than EGFRm LUAD, yet more immunologically active than that of P-SCLC, and this immune profile provides a rationale for integrating immunotherapy with chemotherapy in T-SCLC.
Hui Yu, Meichen Li, Xiao-Die Li et al.· Journal of Translational Med...· 0 citations
ST6GAL1-mediated α2,6-sialylation of EGFR contributes to the maintenance of CSLC-associated paclitaxel resistance through mTOR-SOX2/BMI1 signaling, which identifies ST6GAL1-dependent EGFR sialylation as a potential therapeutic target in CSLC-associated chemoresistance.
Yu-Xi Yang, Bing-Hui Liang, W. Hong et al.· Cancer Drug Resistance· 1 citation
These results uncover a metabolism-epigenetics–cell cycle interface that may represent a therapeutic vulnerability in EGFR-mutant LUAD and identify a glycolysis–H4K8la–GAS2L3 axis that drives noncanonical cell-cycle reprogramming independently of classical Cyclin–CDK activation, thereby promoting acquired osimertinib r...
Shu-Man Zhen, Xiaohui Bai, Shu-Tang Liu et al.· Cell Death Discovery· 0 citations
Results demonstrate for the first time that TP53 expression is dynamically regulated at the transcriptional level through promoter methylation related to the drug tolerance, emphasizing that epigenetic silencing, rather than exclusive genetic loss-of-function, contribute to platinum resistance and underscore the therap...
Sojung Ha, Woo-Young Kim· Biomolecules & Therapeutics· 0 citations
Despite the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib in
EGFR
-mutant non-small cell lung cancer (NSCLC) patients, a subset of drug-tolerant persister (DTP) cells remains. While protein alterations unique to DTPs are crucial for their survival, the mechanisms re...
Hyung-Muck Kang· Discover Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
